Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.88 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.78 |
| ▸ | PRKACA | P17612 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | RORC | P51449 | 2/20 | 0.71 |
| ▸ | WNT3A | P56704 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MGAM | O43451 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | SI | P14410 | 1/20 | 0.62 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102667 | 0.94 | KMT2A (1.00) | KMT2AROCK1PRKACAMEN1WNT3A | |
| SCHEMBL13357346 | 0.88 | ROCK1 (1.00) | KMT2AROCK1PRKACAMEN1WNT3A | |
| SCHEMBL13357345 | 0.88 | WNT3A (0.83) | KMT2AROCK1PRKACAMEN1RORC | |
| SCHEMBL436404 | 0.84 | KMT2A (0.73) | KMT2AROCK1PRKACAMEN1WNT3A | |
| SCHEMBL4265795 | 0.83 | LMNA (0.64) | KMT2AROCK1PRKACAMEN1RAB9A | |
| SCHEMBL14102574 | 0.83 | LMNA (0.67) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL1726157 | 0.82 | WNT3A (1.00) | KMT2AROCK1PRKACAMEN1WNT3A | |
| SCHEMBL3603577 | 0.81 | MEN1 (0.67) | KMT2AMEN1RAB9ANPC1LMNA | |
| SCHEMBL14102962 | 0.81 | KMT2A (0.77) | KMT2AROCK1PRKACAMEN1WNT3A | |
| SCHEMBL13213633 | 0.81 | KMT2A (0.76) | KMT2AROCK1PRKACAMEN1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | claimed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | KMT2A 2486/4885ROCK1 102/4885PRKACA 81/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | KMT2A 4046/4885ROCK1 28/4885PRKACA 1087/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | KMT2A 2406/4885ROCK1 93/4885PRKACA 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.